Table 3.
Treatment-related adverse events in the 2 groups (n, %).
| Adverse event | Novel anti-HER2 ADCs (n = 73) | T-DM1 (n = 71) | ||
|---|---|---|---|---|
| Any grade | Grade3~4 | Any grade | 3~4 | |
| Neutropenia | 33 (45.2) | 15 (20.5) | 13 (18.3) | 4 (5.6) |
| Leukopenia | 26 (35.6) | 6 (8.2) | 13 (18.3) | 2 (2.8) |
| Anemia | 28 (38.4) | 5 (6.8) | 15 (21.1) | 4 (5.6) |
| Thrombocytopenia | 11 (15.1) | 3 (4.1) | 38 (53.5) | 20 (28.1) |
| Diarrhea | 13 (17.8) | 6 (8.2) | 6 (8.5) | 0 |
| Constipation | 11 (15.1) | 0 | 5 (7.0) | 0 |
| Nausea | 56 (76.7) | 9 (12.3) | 5 (7.0) | 0 |
| Vomiting | 34 (46.5) | 8 (11.0) | 3 (4.2) | 0 |
| Fatigue | 48 (65.8) | 4 (5.4) | 36 (49.3) | 2 (2.8) |
| Decreased appetite | 31 (42.4) | 0 | 14 (19.7) | 0 |
| Elevated transaminase | 11 (15.1) | 2 (2.7) | 16 (22.5) | 4 (5.6) |
| Peripheral Neuropathy | 20 (27.4) | 3 (4.1) | 6 (8.5) | 0 |
| Interstitial lung disease | 4 (5.4) | 1 (1.4) | 1 (1.4) | 0 |
Abbreviations: HER2:, human epidermal growth factor receptor 2; ADCs: antibody-drug conjugates; T-DM1: trastuzumab emtansine.